
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
VA funds first study on psychedelic-assisted therapy for Veterans
This funding is a part of VA’s broader effort announced in January to gather definitive scientific evidence on the potential efficacy and safety of psychedelic compounds such as MDMA and psilocybin when used in conjunction with psychotherapy to treat Veterans with PTSD, depression, and other related conditions.
RFK could be ‘dangerous’ to psychedelics reform as top federal health official by making issue seem ‘kooky,’ Michael Pollan says
“Psychedelics should be approved because the science is good, not because they have a fan in the White House,” he said, adding that while some in the psychedelics community are “fervently hoping” that Kennedy and other pro-reform Trump picks will “force the hand” of the Food and Drug Administration (FDA) to approve psychedelics as medicine, “politically, I don’t think that’s a good way to go, long-term.”
FDA's psychedelic reckoning
All of this, including insights extracted from the setbacks at Lykos and Compass, bodes well for Cybin, a Toronto-based biopharmaceutical company which has initiated a Phase 3 pivotal trial of deuterated psilocin (CBY003) for major depressive disorder (MDD).
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study
These findings elucidate the complex interplay between challenging experiences and adaptive responses in psychedelic contexts, offering insights for optimising therapeutic protocols and enhancing safety in both clinical and non-clinical settings.
MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model-informed analysis
This model-informed drug development approach was employed to inform drug–drug interaction potential and predict pharmacokinetics of clinically relevant dosing regimens of MDMA.
The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD
To date, the conceptual framework for this treatment has not been described in the scientific literature. This omission has contributed to misunderstandings about both the theoretical underpinnings of this modality and the therapeutic approach that emerges from it. This paper delineates the psychotherapeutic concepts, theories, and historical antecedents underlying the inner-directed approach to MDMA-Assisted Therapy for PTSD.
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
We suggest actionable recommendations for how the field can transcend current conceptualizations and provide guidance on best practices until the next generation of measures is validated.
Considering distinct positive emotions in psychedelic science
In this review, we discuss psychedelics’ acute subjective and persisting therapeutic effects, outline the science of positive emotions, and highlight the value in considering distinct positive emotions in psychedelic science.
Fragile promise of psychedelics in psychiatry
The US clinical market for ketamine, estimated at $3.1bn in 2022 and expected to expand at 10.6% a year until 2030, is just one of many signs of renewed interest in the use of psychedelics to treat psychiatric conditions.
Personal psychedelic experience as a training qualification for facilitators: A thematic analysis of qualitative interviews with psilocybin experts
Novel state-legal psychedelic paradigms create a real-world opportunity to assess associations between facilitators’ personal psychedelic experience and the safety and outcomes of psychedelic services.
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals
As psychedelics continue to garner popular and scientific interest, results indicate a pressing need for additional formal training to provide balanced, evidence-based information from trusted sources.
What should constitute a control condition in psychedelic drug trials?
When appropriate control conditions are lacking, it becomes difficult to disentangle placebo and expectation effects from medication effects. Here we explore the neurobiology of placebo and expectation effects, alongside the methodological considerations for selecting suitable control conditions in psychedelic trials.
Healing, spiritual purposes drive many veterans’ use of psychedelics
Most U.S. military veterans who have used psychedelics reported in a recent study that they pursued the substances for healing or spiritual exploration, and over 80% said they benefited from the experience – even those who had challenging outcomes.
Going underground: Demographics, services, and best practices endorsed by practitioners providing support for naturalistic psychedelic use
Although some people report naturalistic psychedelic use with so-called “underground” practitioners, little is known about PAT that occurs outside of controlled clinical settings or perspectives of these practitioners.
Global trends in psychedelic microdosing: Demographics, substance testing behavior, and patterns of use
Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored.
Santo Daime's MeToo moment - A law suit in Brazil, decades of earlier incidents, and wider questions about safety in psychedelic churches
Basically, the MeToo movement is belatedly catching up with the Daime world. Paulo Roberto is not the only male leader or member of a Daime church being outed as a predator. We are collectively in a moment of reckoning that has been a long time in coming. Goldman tells me expects more cases of misconduct in Daime churches to emerge.
What will a Trump administration do with psychedelics?
As Donald Trump prepares to take office in January, psychedelics are likely to remain a popular issue among members of his inner circle.
An early economic analysis of medical cannabis for the treatment of chronic pain
These findings highlight the substantial cost saving that CBMPs may represent for the treatment of chronic pain patients, and the benefits for healthcare providers as a treatment for this often hard-to-treat population.
Psychedelics vs. traditional treatments — how do they stack up for mental health disorders? – Part 1
This review examines the distinct mechanisms, therapeutic potentials, and limitations of both conventional and psychedelic-assisted treatments, providing a comprehensive analysis of their roles in modern psychiatric care.
Nausea, lion's breath, and ondansetron
Nausea is one of the most common and unpleasant sensations associated with use of almost all psychedelic agents. In this video and written blog post I share my perspective on the occurrence of nausea with psychedelic, strategies that persons could use to manage nausea, and somatic techniques and mindful visualizations to potentially deepen therapeutic benefits or provide an avenue for cathartic experience.